Robert W. Baird analyst Eric Coldwell maintained a Buy rating on Mckesson Corp . on Tuesday, setting a price target of $240, which is approximately 23.48% above the present share price of $194.36.
Coldwell expects Mckesson Corp. to post earnings per share (EPS) of $4.19 for the third quarter of 2021.
The current consensus among 10 TipRanks analysts is for a Strong Buy rating of shares in McKesson, with an average price target of $225.33.
The analysts price targets range from a high of $257 to a low of $205.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $59.14 billion and a net profit of $1.07 billion. The company's market cap is $30.06 billion.
According to TipRanks.com, Robert W. Baird analyst Eric Coldwell is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 14.1% and a 63.04% success rate.
Incorporated in 1833, Texas-based McKesson Corp (NYSE:MCK). provides pharmaceuticals, health information technology, medical supplies, and care management tools. The company operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, International, and Medical-Surgical Solutions.